TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies

References

• Adams D, Lozeron P, Lacroix C. Amyloid neuropathies. Curr Opin Neurol. 2012 Oct;25(5):564–572.
   PubMed Web of Science ®Google Scholar
• Coutinho P, Martins Da Silva A, Lopes Lima J, et al. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG PeCP, Falcao de Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; 1980. p. 88–98.
   Google Scholar
• Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952 Sep;75(3):408–427.
   PubMed Web of Science ®Google Scholar
• Kato-Motozaki Y, Ono K, Shima K, et al. Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus. J Neurol Sci. 2008 Jul 15;270(1–2):133–140.
   PubMed Web of Science ®Google Scholar
• Sousa A, Coelho T, Barros J, et al. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet. 1995 Dec 18;60(6):512–521.
   PubMed Web of Science ®Google Scholar
• Sousa A, Andersson R, Drugge U, et al. Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence. Hum Hered. 1993 Sep-Oct;43(5):288–294.
   PubMed Web of Science ®Google Scholar
• Saraiva MJ, Birken S, Costa PP, et al. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest. 1984 Jul;74(1):104–119.
   PubMed Web of Science ®Google Scholar
• Saraiva MJ, Costa PP, Goodman DS. Genetic expression of a transthyretin mutation in typical and late-onset Portuguese families with familial amyloidotic polyneuropathy. Neurology. 1986 Nov;36(11):1413–1417.
   PubMed Web of Science ®Google Scholar
• Harada T, Kito S, Shimoyama M, et al. Genetic and clinical studies of Japanese patients with familial amyloid polyneuropathy. Eur Neurol. 1989;29(1):48–52.
   PubMed Web of Science ®Google Scholar
• Wallace MR, Conneally PM, Long GL, et al. Molecular detection of carriers of hereditary amyloidosis in a Swedish-American family. Am J Med Genet. 1986 Oct;25(2):335–341.
   PubMed Web of Science ®Google Scholar
• Holt IJ, Harding AE, Middleton L, et al. Molecular genetics of amyloid neuropathy in Europe. Lancet. 1989 Mar 11;1(8637):524–526.
   PubMed Web of Science ®Google Scholar
• Reilly MM, Adams D, Booth DR, et al. Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy. Brain. 1995 Aug;118(Pt 4):849–856.
   PubMed Web of Science ®Google Scholar
• Rowczenio DM, Noor I, Gillmore JD, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014 Sep;35(9):E2403–2412.
   PubMed Web of Science ®Google Scholar
• Koike H, Misu K, Ikeda S, et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002 Nov;59(11):1771–1776.
   PubMedGoogle Scholar
• Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993 May 1;341(8853):1113–1116.
   PubMed Web of Science ®Google Scholar
• Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain. 2000 Jul;123(Pt 7):1495–1504.
   PubMed Web of Science ®Google Scholar
• Ericzon B-G, Wilczek HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015 Sep;99(9):1847–1854.
   PubMed Web of Science ®Google Scholar
• Adams D, Théaudin M, Cauquil C, et al. FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep. 2014 Mar;14(3):435.
   PubMed Web of Science ®Google Scholar
• Swiecicki PL, Zhen DB, Mauermann ML, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015 Jun;22(2):123–131.
   PubMed Web of Science ®Google Scholar
• Adams D, Lozeron P, Theaudin M, et al. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid. 2012 Jun;19(Suppl 1):61–64.
   PubMed Web of Science ®Google Scholar
• Dohrn MF, Röcken C, De Bleecker JL, et al. Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol. 2013 Dec;260(12):3093–3108.
   PubMed Web of Science ®Google Scholar
• Luigetti M, Conte A, Del Grande A, et al. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurol Sci. 2013 Jul;34(7):1057–1063.
   PubMed Web of Science ®Google Scholar
• Liu J-Y, Guo Y-J, Zhou C-K, et al. Clinical and histopathological features of familial amyloidotic polyneuropathy with transthyretin Val30Ala in a Chinese family. J Neurol Sci. 2011 May 15;304(1–2):83–86.
   PubMed Web of Science ®Google Scholar
• Revision of World Population Prospects. 2015. [cited 2015]. Available from: http://esa.un.org/unpd/wpp/.
   Google Scholar
• Parman Y, Adams D, Obici L, et al. 60 years of TTR-FAP in Europe - where are we now? A European Network approach to defining the epidemiology and management patterns for transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S3–S13.
   PubMed Web of Science ®Google Scholar
• Zhen DB, Swiecicki PL, Zeldenrust SR, et al. Frequencies and geographic distributions of genetic mutations in transthyretin- and non-transthyretin-related familial amyloidosis. Clin Genet. 2015 Oct;88(4):396–400.
   PubMed Web of Science ®Google Scholar
• Araki S, Ando Y. Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto, Japan (1967-2010). Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(7):694–706.
   PubMed Web of Science ®Google Scholar
• Lozeron P, Lacroix C, Theaudin M, et al. An amyotrophic lateral sclerosis-like syndrome revealing an amyloid polyneuropathy associated with a novel transthyretin mutation. Amyloid. 2013 Sep;20(3):188–192.
   PubMed Web of Science ®Google Scholar
• Theaudin M, Yalo B, Mincheva Z, et al. Multifocal neuropathy with upper limb onset as a frequent phenotype in familial amyloid polyneuropathy in France. Neurology. 2013;80(Meeting abstracts 1):P05.065..
   Google Scholar
• Dyck PJ, Davies JL, Litchy WJ, et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology. 1997 Jul;49(1):229–239.
   PubMed Web of Science ®Google Scholar
• Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: A multinational natural history study. Neurology. 2015 Aug 25;85(8):675–682.
   PubMed Web of Science ®Google Scholar
• Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):152–158.
   PubMed Web of Science ®Google Scholar
• Mariani -L-L, Lozeron P, Théaudin M, et al. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in france. Ann Neurol. 2015;78(6):901–916.
   PubMed Web of Science ®Google Scholar
• Yang NC, Lee M-J, Chao CC, et al. Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser. Neurology. 2010 Aug 10;75(6):532–538.
   PubMed Web of Science ®Google Scholar
• Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol. 1999;41(Suppl 1):8–13.
   PubMed Web of Science ®Google Scholar
• Suanprasert N, Berk JL, Benson MD, et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials. J Neurol Sci. 2014 Sep 15;344(1–2):121–128.
   PubMed Web of Science ®Google Scholar
• Pruppers MH, Merkies IS, Faber CG, et al. The Val30Met familial amyloid polyneuropathy specific Rasch-built overall disability scale (FAP-RODS). JPNS. 2015;20(3):319–327.
   Google Scholar
• Kollmer J, Hund E, Hornung B, et al. In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain. 2015 Mar;138(Pt 3):549–562.
   PubMed Web of Science ®Google Scholar
• Ericzon B, Wilczek H, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–1854.
   PubMed Web of Science ®Google Scholar
• Algalarrondo A, Teresa Antonini T, Théaudin M, et al. Prediction of long-term survival after liver transplantation for familial transthyretin amyloidosis. JACC. 2015;66(19):2154–2156.
   Web of Science ®Google Scholar
• Calculator for liver transplantation TTR-FAP. [cited 2015 Nov 10]. Available from: http://www.nnerf.fr/attrtransplantscore/.
   Google Scholar
• Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010 Jul 27;75(4):324–327.
   PubMed Web of Science ®Google Scholar
• Beirão JM, Malheiro J, Lemos C, et al. Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis. Amyloid. 2015 Mar;22(1):31–35.
   PubMed Web of Science ®Google Scholar
• Maia LF, Magalhães R, Freitas J, et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):159–167.
   PubMed Web of Science ®Google Scholar
• Adams D, Mincheva Z, Antonini T, et al. Worsening of Familial Amyloid Polyneuropathy after LT: chracteristics of patients. JPNS. 2013;18(suppl):S2.
   Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):819–829.
   PubMed Web of Science ®Google Scholar
• Suhr OB, Coelho T, Buades J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015;10(1):109.
   PubMed Web of Science ®Google Scholar
• APOLLO: the study of an investigational drug, patisiran (ALN-TTR02), for the treatment of transthyretin (TTR)-mediated amyloidosis. 2015 Aug [cited 2015 Aug 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01960348?term=apollo+ttr02&rank=1.
   Google Scholar
• Efficacy and Safety of ISIS-TTR Rx in Familial Amyloid Polyneuropathy. [cited 2015 Aug 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT01737398?term=isis+ttr+RX&rank=1.
   Google Scholar
• Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015;373(12):1106–1114.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Connelly S, Fearns C, et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol. 2012 Aug 10;421(2–3):185–203.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins Da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012 Aug 21;79(8):785–792.
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. Jama. 2013 Dec 25;310(24):2658–2667.
   PubMed Web of Science ®Google Scholar
• Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9629–9634.
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Da Silva AM, et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013 Nov;260(11):2802–2814.
   PubMed Web of Science ®Google Scholar
• Merlini G, Planté-Bordeneuve V, Judge DP, et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013 Dec;6(6):1011–1020.
   PubMed Web of Science ®Google Scholar
• Lozeron P, Théaudin M, Mincheva Z, et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2013 Dec;20(12):1539–1545.
   PubMed Web of Science ®Google Scholar
• Coutinho MC, Cortez-Dias N, Cantinho G, et al. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging. 2013 Sep;6(5):627–636.
   PubMed Web of Science ®Google Scholar
• Adams D, Théaudin M, Lozeron P, et al. Management of stage 1 TTR FAP: French experience. Orphanet J Rare Dis. 2015;10(Suppl 1):39.
   PubMed Web of Science ®Google Scholar
• EMA. Vyndaqel: EPAR - Product Information. [cited 2011 Nov 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002294/WC500117861.pdf
   Google Scholar
• Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004 May;84(5):545–552.
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Tojo K, Morita H, et al. Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis. Amyloid. 2015 Jun;22(2):79–83.
   PubMed Web of Science ®Google Scholar
• Adams D, Coelho T, Conceicao I, et al. Phase 2 Open-Label Extension Study (OLE) of patisiran, an investigational RNAi therapeutic for Familial Amyloid Polyneuropathy (FAP). Ann Neurol. 2015;78(S19):S113.
   Google Scholar
• clinicaltrialgov. The study of an investigational drug, ALN-TTR02, for the treatment of transthyretin (TTR)-mediated amyloidosis. [cited 2016 Jan 29]. Available from: https://clinicaltrialsgov/ct2/show/study/NCT01960348?term=PATISIRAN&rank=2&show_locs=Y.
   Google Scholar
• Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts. 2014 Mar;5(1):45–54.
   PubMedGoogle Scholar
• Vieira M, Gomes JR, Saraiva MJ. Transthyretin induces insulin-like growth factor I nuclear translocation regulating its levels in the hippocampus. Mol Neurobiol. 2015 Jun;51(3):1468–1479.
   PubMed Web of Science ®Google Scholar
• ENDEAVOUR: phase 3 multicenter study of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated familial amyloidotic cardiomyopathy (FAC). [cited 2016 Feb 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02319005?term=NCT02319005&rank=1.
   Google Scholar
• Benson MD, Kluve-Beckerman B, Zeldenrust SR, et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006 May;33(5):609–618.
   PubMed Web of Science ®Google Scholar
• Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid. 2012 Jun;19(Suppl 1):43–44.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of ISIS-TTR Rx in familial amyloid polyneuropathy. [cited 2015 Aug 7]. Available from: https://clinicaltrialsgov/ct2/show/study/NCT01737398?term=ISIS+TTR+fap&rank=2.
   Google Scholar
• Dyck P, Wang A, Kincaid J, et al. Evaluation of modifications of NIS+7 score in oligonucleotide trials in TTR-FAP. J Peripher Nervous Syst. 2015;20:132–133.
   Web of Science ®Google Scholar
• Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010 Nov 4;468(7320):93–97.
   PubMed Web of Science ®Google Scholar
• Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy (ATTR-ACT). [cited 2015 Aug 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT01994889?term=tafamidis+cardiac&rank=4.
   Google Scholar
• Hawkins PN, Ando Y, Dispenzeri A, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625–638.
   PubMed Web of Science ®Google Scholar
• Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012 May;33(9):1120–1127.
   PubMed Web of Science ®Google Scholar